Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Jilin Aodong Makes $2 Million Initial Investment in Vital Therapies

publication date: Apr 7, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jilin Aodong Medicine Industry Group (吉林敖東藥業集團股份有限公) will make a small $2 million investment into Vital Therapies, a San Diego company that is developing a medical device for patients with liver failure. The initial $2 million investment will purchase a stake in Vital Therapies of between 5% and 6%. If Vital Therapies obtains SFDA approval for its device in the next six months, Aodong will invest an additional $25 million in Vital Therapies. More details....

Stock Symbol: (SHE: 000623)     Share this with colleagues:  

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners